Literature DB >> 29083131

Abiraterone in Metastatic Prostate Cancer.

Karim Fizazi1, Kim N Chi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29083131     DOI： 10.1056/NEJMc1711029

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  A cost-utility analysis of apalutamide for metastatic castrationsensitive prostate cancer.

Authors:  Ambica Parmar; Narhari Timilshina; Urban Emmenegger; Martin Smoragiewicz; Beate Sander; Shabbir Alibhai; Kelvin K W Chan
Journal:  Can Urol Assoc J       Date:  2022-03       Impact factor: 2.052

2.  Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

Authors:  Tetsuro Ito; Laura Grant; Bryony R Duckham; Amanda J Ribbands; Adam Gater
Journal:  Adv Ther       Date:  2018-11-10       Impact factor: 4.070

3.  Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

Authors:  Karen A Autio; Emmanuel S Antonarakis; Tina M Mayer; Daniel H Shevrin; Mark N Stein; Ulka N Vaishampayan; Michael J Morris; Susan F Slovin; Elisabeth I Heath; Scott T Tagawa; Dana E Rathkopf; Matthew I Milowsky; Michael R Harrison; Tomasz M Beer; Arjun V Balar; Andrew J Armstrong; Daniel J George; Channing J Paller; Arlyn Apollo; Daniel C Danila; Julie N Graff; Luke Nordquist; Erica S Dayan Cohn; Kin Tse; Nicole A Schreiber; Glenn Heller; Howard I Scher
Journal:  Eur Urol Open Sci       Date:  2021-11-17

4.  Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP.

Authors:  Stéphane Supiot; Loic Campion; Pascal Pommier; Mélanie Dore; Clément Palpacuer; Séverine Racadot; Emmanuel Rio; Gérard A Milano; Céline Mahier-Ait Oukhatar; Christian Carrie
Journal:  Oncotarget       Date:  2018-04-24

Review 5.  Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion.

Authors:  Daniele Santini; Alfredo Berruti; Massimo Di Maio; Giuseppe Procopio; Sergio Bracarda; Toni Ibrahim; Francesco Bertoldo
Journal:  ESMO Open       Date:  2020-03

6.  Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Andrew J Armstrong; Jun Luo; David M Nanus; Paraskevi Giannakakou; Russell Z Szmulewitz; Daniel C Danila; Patrick Healy; Monika Anand; William R Berry; Tian Zhang; Michael R Harrison; Changxue Lu; Yan Chen; Giuseppe Galletti; Joseph D Schonhoft; Howard I Scher; Richard Wenstrup; Scott T Tagawa; Emmanuel S Antonarakis; Daniel J George; Susan Halabi
Journal:  JCO Precis Oncol       Date:  2020-10-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.